Halozyme Therapeutics, Inc. (LON:0J2O)
60.47
-0.94 (-1.53%)
At close: Apr 30, 2025
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
2.32M GBP
Profits / Employee
1.01M GBP
Market Cap
5.58B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Halozyme Therapeutics News
- 8 days ago - Halozyme files patent lawsuit against Merck over injectable Keytruda - Seeking Alpha
- 8 days ago - Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation - PRNewsWire
- 10 days ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
- 20 days ago - Peering Into Halozyme Therapeutics's Recent Short Interest - Benzinga
- 21 days ago - Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe - Seeking Alpha
- 21 days ago - Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - PRNewsWire
- 23 days ago - J&J, Halozyme get EU nod for Darzalex SC to treat multiple myeloma - Seeking Alpha
- 23 days ago - European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - PRNewsWire